Showing results (41-50 of 415) with videos related to

Sort By:
Pageof 42
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|May 16, 2002
The progesterone receptor exon 4 Val660Leu G/T polymorphism and risk of breast cancer in Australian womenAmanda B Spurdle, John L Hopper, Xiaoqing Chen, et al.
Schizophrenia Bulletin|November 20, 2018
Is Schizophrenia a Risk Factor for Breast Cancer?-Evidence From Genetic DataEnda M Byrne, Manuel A R Ferreira, Angli Xue, et al.
Cancer Letters|September 21, 2024
Targeting RNA helicase DDX3X with a small molecule inhibitor for breast cancer bone metastasis treatmentPaul T Winnard, Farhad Vesuna, Guus M Bol, et al.
Carcinogenesis|February 12, 2011
Breast cancer stem cells: treatment resistance and therapeutic opportunitiesFares Al-Ejeh, Chanel E Smart, Brian J Morrison, et al.
Breast Cancer Research and Treatment|February 4, 2009
Frequent somatic mutations of GATA3 in non-BRCA1/BRCA2 familial breast tumors, but not in BRCA1-, BRCA2- or sporadic breast tumorsJeremy M Arnold, David Y H Choong, Ella R Thompson, et al.
Breast Cancer Research and Treatment|May 16, 2008
The BARD1 Cys557Ser polymorphism and breast cancer risk: an Australian case-control and family analysisSharon E Johnatty, Jonathan Beesley, Xiaoqing Chen, et al.
Plos Genetics|June 9, 2015
A Common Cancer Risk-Associated Allele in the hTERT Locus Encodes a Dominant Negative Inhibitor of TelomeraseAnagha Killedar, Michael D Stutz, Alexander P Sobinoff, et al.
Breast Cancer Research : BCR|August 19, 2007
BCoR-L1 variation and breast cancerFelicity Lose, Jeremy Arnold, David B Young, et al.
Breast Cancer Research and Treatment|November 19, 2009
Pooled analysis indicates that the GSTT1 deletion, GSTM1 deletion, and GSTP1 Ile105Val polymorphisms do not modify breast cancer risk in BRCA1 and BRCA2 mutation carriersAmanda B Spurdle, Paul Fahey, Xiaoqing Chen, et al.
Pharmacogenetics|July 27, 2002
The CYP3A4*1B polymorphism has no functional significance and is not associated with risk of breast or ovarian cancerAmanda B Spurdle, Bryan Goodwin, Ecushla Hodgson, et al.
Pageof 42